-
-
-
-
-
-
-
Wedbush Downgrades Tourmaline Bio (TRML) to Neutral Post Acquisition
-
-
-
-
-
-
-
Tourmaline Bio (TRML) Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and CKD
-
-
-
-
-
-
-
Tourmaline Bio (TRML) Misses Q4 EPS by 86c
-
-
-
-
-
-
-
Tourmaline Bio (TRML) Misses Q3 EPS by 78c
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Tourmaline Bio (TRML)
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

